Conducting MRI trials in Alzheimer's patients: Challenges and Guidelines

Area of Science:

• Neuroimaging
• Clinical Trials
• Alzheimer's Disease Research

Background:

• Pharmaceutical interventions and neuroimaging in Alzheimer's disease (AD) research face significant logistical and methodological challenges.
• Early-phase clinical trials, particularly those using high-field magnetic resonance imaging (MRI), encounter substantial recruitment and execution hurdles.

Purpose of the Study:

• To outline early-phase experiences from a 7-tesla (7T) functional MRI (fMRI) clinical trial for mild cognitive impairment (MCI) and mild AD.
• To highlight key recruitment barriers and provide practical recommendations for optimizing high-field MRI drug studies in AD research.

Main Methods:

• Perspective paper detailing experiences from a 7T fMRI clinical trial involving individuals with MCI and mild AD.
• Analysis of recruitment data from an initial pool of 1,000 patients, with a focus on screening, inclusion criteria, and identified barriers.

Main Results:

• Only 6% of clinically diagnosed MCI or mild AD patients (475 out of 1,000) met all inclusion criteria after screening.
• Major recruitment barriers included comorbidities, difficulties with blood draws, procedural miscommunication, and unreported medical conditions found during MRI.
• Effective communication, caregiver involvement, and internal team coordination were crucial for medical history accuracy and protocol adherence.

Conclusions:

• Strict eligibility criteria in high-field MRI drug studies, while ensuring data quality, severely limit recruitment and feasibility.
• Recommendations are provided to optimize recruitment, screening, protocol execution, and balance scientific rigor with clinical constraints in AD research.